RET and non-small cell lung carcinoma: Future studies and clinical trials will shed light onto what drug is most optimal for the treatment of RET-rearranged NSCLC cases and what combinations of other tyrosine kinases or chemotherapies should be used to ensure that a patient achieves an optimal response.